MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
Merck Sharp & Dohme (MSD) has agreed to acquire Cidara Therapeutics in a transaction valued at approximately $9.2 billion, following encouraging results from the company’s phase 2b trial of its lead ...
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Looking back at 2025 as a breakthrough year for podcasts on YouTube, one thing stands out: viewership on TVs is higher than ever. In fact, viewers watched over 700 million hours of podcasts on living ...
Abstract: The programmable envelope shaping technique of high-repetition-rate optical pulse sequences with low-speed modulation is summarized in this letter. First, we reviewed our work on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results